NCT03301038View on ClinicalTrials.gov

Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 25, 2018

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2030

Conditions
Idiopathic Infantile Hypercalcaemia - Severe FormGenetic DiseaseHypercalcemia, Idiopathic, of InfancyHypercalciuric HypercalcemiaIdiopathic Infantile Hypercalcemia - Mild FormHypercalciuria
Interventions
DRUG

Rifampin

Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.

Trial Locations (1)

19104

RECRUITING

Children's Hospital of Philadelphia, Philadelphia

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Children's Hospital of Philadelphia

OTHER